NTRK3 and lung adenocarcinoma: Rapid response to fifth-line brigatinib plus entrectinib in an <i>ALK</i>-rearranged lung adenocarcinoma with an acquired <i>ETV6</i>-<i>NTRK3</i> fusion: a case report.